Document Detail

Secondary systemic amyloidosis: response and survival in 64 patients.
MedLine Citation:
PMID:  2067409     Owner:  NLM     Status:  MEDLINE    
From 1956 through 1989, 38 men and 26 women were seen at the Mayo Clinic with biopsy-proven AA. The underlying disorder was rheumatic disease in 42, infectious disease in 11, inflammatory bowel disease in 6, and other causes in 5. All patients were symptomatic at the time of diagnosis. Fifty-eight of the 64 patients had proteinuria or renal insufficiency. Fourteen also had significant symptoms of gastrointestinal amyloid, and 6 had amyloid goiter. None of the patients had symptomatic cardiac involvement, and only 3 had palpable hepatomegaly. Renal, gastric, rectal, fat, and marrow biopsies were positive for amyloid in 100%, 94%, 82%, 58%, and 46% of tested patients, respectively. The median survival of the entire group was 24.5 months. Thirty-five of the 47 deceased patients died as a direct result of their amyloidosis, primarily from complications of renal failure. Nine were successfully treated and had regression of the disease. Two with bronchiectasis responded to long-term cyclic antibiotic therapy, as did 1 patient with osteomyelitis. One patient with inflammatory bowel disease responded to surgical resection, and 1 with familial Mediterranean fever responded to colchicine. Four patients with rheumatic disease were treated with cyclophosphamide (in 2) and methotrexate (in 2), with complete resolution of their renal disease. All 9 successfully treated patients are alive, with a median follow-up of 58 months. Statistical analysis revealed that creatinine values greater than or equal to 2.0 mg/dl (P less than 0.003) and a serum albumin value less than 2.5 g/dl (P less than 0.02) were associated with a poorer survival. The single strongest variable associated with poor survival was a serum creatinine level greater than 2 mg/dl at presentation, with a median survival of 11.2 months compared to patients with a creatinine level less than 2.0 mg/dl, with a median survival of 56.9 months.
M A Gertz; R A Kyle
Related Documents :
20696639 - Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with...
6249009 - Ruptured congenital mesoblastic nephroma: chemotherapy and irradiation as adjuvants to ...
11458759 - The role of lymphadenectomy in the radical nephrectomy for renal cell carcinoma.
9626229 - Resection of metastatic renal cell carcinoma.
8516989 - Survival characteristics of metastatic renal cell carcinoma patients treated with lymph...
18026989 - Prognostic role of cd44 cell adhesion molecule expression in primary and metastatic ren...
16986009 - Salvage cryosurgery-how i do it.
22065519 - Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with...
14770439 - Treatment of atypical neurocytomas.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Medicine     Volume:  70     ISSN:  0025-7974     ISO Abbreviation:  Medicine (Baltimore)     Publication Date:  1991 Jul 
Date Detail:
Created Date:  1991-08-15     Completed Date:  1991-08-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2985248R     Medline TA:  Medicine (Baltimore)     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  246-56     Citation Subset:  AIM; IM    
Dysproteinemia Clinic, Mayo Clinic, Rochester, Minnesota 55905.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Amyloid / analysis
Amyloidosis / diagnosis,  drug therapy,  etiology,  mortality*,  pathology
Diagnosis, Differential
Follow-Up Studies
Middle Aged
Minnesota / epidemiology
Proportional Hazards Models
Retrospective Studies
Rheumatic Diseases / complications
Survival Rate
Time Factors
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  31P NMR spectroscopy in chronic adriamycin cardiotoxicity.
Next Document:  Poikilothermia in man: pathophysiology and clinical implications.